Brittany Kaiser, Chief Executive Officer
Brittany Kaiser is a serial entrepreneur and activist, recognized globally for her expertise in technology and legislative reform. She has advised governments, companies, and campaigns on policy and strategy throughout her career. Notably, Ms. Kaiser is a former business development director and whistleblower for Cambridge Analytica, subsequently focusing on ethical technology through education and legislative advocacy. She is a co-founder and President of the Own Your Data Foundation and has guided three companies to public listing on Nasdaq, including Gryphon Digital Mining (now American Bitcoin). She is also the best-selling author of "Targeted" and the primary subject of the Netflix documentary "The Great Hack."

Wes Levitt, Chief Financial Officer
Wes Levitt oversees Alpha Compute Corp.'s finance, accounting, and capital markets operations, a role he assumed in October 2025 during the company's prior iteration as AlphaTON Capital. Previously, Mr. Levitt served as Co-CIO at Alpha Sigma Capital Advisors, where he was responsible for investment strategy, asset allocation, and portfolio oversight for a prominent blockchain industry fund. He also held the position of Head of Strategy at Theta Labs, where he directed global corporate strategy, marketing, analytics, and token infrastructure initiatives. His experience includes serving as Chief Financial Officer for a special-purpose acquisition company (SPAC).

Enzo Villani, Executive Chairman & Chief Investment Officer
Enzo Villani serves as Executive Chairman and Chief Investment Officer for Alpha Compute Corp. He played a significant role in developing the core firmware for Telegram's Cocoon AI launch and in securing hardware-level encryption capabilities for the company. Mr. Villani emphasizes Alpha Compute's strategic position as a specialized and scalable AI compute company, aiming to lead in the rapidly evolving AI infrastructure market.

Yury Mitin, Chief Business Development Officer
Yury Mitin is the Chief Business Development Officer of Alpha Compute Corp. He was part of the leadership team when the company, then AlphaTON Capital, focused on developing the TON digital asset treasury strategy within the Telegram ecosystem.

1. Clinical Development and Regulatory Approval Risk: Portage Biotech Inc. is primarily a research and development company with its product candidates, such as INT230-6, in early-stage clinical trials (Phase I/II). The biotechnology drug development process is inherently uncertain, lengthy, and expensive, with a high rate of failure at each clinical trial stage due to issues with efficacy, safety, or unforeseen complications. There is no guarantee that any of the company's product candidates will successfully complete clinical trials or receive the necessary regulatory approvals (e.g., from the FDA or EMA). Failure to successfully advance product candidates through clinical development or to obtain regulatory approvals would severely impact the company's ability to generate revenue and its overall business viability.
2. Funding and Liquidity Risk: As a biotechnology company focused on research and development without currently marketed products generating substantial revenue, Portage Biotech Inc. is expected to incur significant operating expenses for its R&D activities and clinical trials. The company will require substantial additional capital to continue funding its development programs and to pursue potential commercialization. The ability to raise this capital through equity financing, debt, or strategic partnerships will depend on various factors, including the progress of its pipeline, market conditions, and investor confidence. There is a risk that adequate funding may not be available on favorable terms or at all, which could force the company to delay, scale back, or abandon its development efforts.
3. Intellectual Property Risk: The success and value of Portage Biotech Inc. are heavily dependent on its ability to obtain, maintain, and protect its proprietary technologies, drug candidates, and discoveries through patents and other intellectual property rights. There is a risk that the company's patent applications may not be granted, that existing patents may be challenged, invalidated, or circumvented by competitors, or that they may not provide adequate protection against competitive products or technologies. Intellectual property disputes or the inability to effectively protect its intellectual property could significantly undermine the company's competitive position, diminish its asset value, and negatively affect its future prospects.